Original White Feather Rice Intranet
Highlights
As one of the major diseases that threaten public health, liver disease has also attracted much attention in the related drug market. According to data from Minenet, the market scale of Chinese patent medicine for liver disease in China's retail pharmacy terminals (urban physical pharmacies + online pharmacies) has continued to expand in recent years, exceeding 2 billion yuan in the first half of 2023, and is expected to exceed 4 billion yuan for the whole year. The TOP10 Chinese patent medicines for liver diseases were released, Pien Tze Huang and Liver Protection Tablets sold more than 100 million yuan, the growth rate of the three brands exceeded 20%, and Sunflower Liver Protection Tablets sprinted to 1 billion gold products.
Sales of proprietary Chinese medicines for liver diseases in retail pharmacies in China in recent years (unit: 100 million yuan)
Source: Minenet Grid Bureau Database
According to data from Minenet, the market size of Chinese patent medicine for liver disease in China's retail pharmacy terminals (urban physical pharmacies + online pharmacies) has continued to expand in recent years, exceeding 2 billion yuan in the first half of 2023, and is expected to exceed 4 billion yuan for the whole year. From the perspective of the manufacturer pattern, Pien Tze Huang, Sunflower Pharmaceutical, and Yibai Pharmaceutical are in the lead.
肝病中成药TOP10,片仔癀、护肝片大卖过亿
In the first half of 2023, China's top 10 retail pharmacies terminal liver disease proprietary medicine products (unit: 100 million yuan)
Source: Minenet Grid Bureau Database
Note: Sales of less than 100 million yuan are indicated by *, and the growth rate of the red is more than 20%
Among the top 10 products, Pien Tze Huang, Liver Protection Tablets and Gentian Liver Pills ranked among the top three, among which the growth rate of Liver Protection Tablets was the fastest, and the sales growth rate of 4 products exceeded 20%, including Liver Protection Tablets, Shugan Yiyang Capsules, Babaodan Capsules and Gentian Liver Pills (Water Pills).
Sales of Pien Tze Huang in China's retail pharmacies in recent years (unit: 100 million yuan)
Source: Minenet Grid Bureau Database
Pien Tze Huang is the exclusive product of Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd., which is used for acute and chronic viral hepatitis, carbuncle boils, nameless swelling and poison, bruises and various inflammations caused by heat poisoning and blood stasis. According to data from Minenet, Pien Tze Huang's terminal sales of retail pharmacies in China will exceed 1 billion yuan in the first half of 2023. It is understood that the company will do excellent Pien Tze Huang, strengthen cosmetics, expand a series of drugs and health foods, continue to consolidate and deepen the core position of Pien Tze Huang, and focus on creating Pien Tze Huang series of drugs, cosmetics and health care products. In terms of channel layout, on the basis of covering nearly 400 Pien Tze Huang experience centers across the country, the company focuses on expanding mainstream chain channels, and through its wholly-owned subsidiary, Fujian Pien Tze Huang Health Technology, it has established a full-category strategic partnership with many well-known leading chains such as Laobaimin, Yifeng, Shuyu Civilian, Jianzhijia, Yixintang, Guoda Pharmacy, etc., to achieve terminal store coverage of more than 100,000. In Fujian, Guangdong, Beijing, Shandong, Jiangsu, Zhejiang, Shanghai and other key markets to form a relatively complete market layout.
The three major brands rose by more than 20%, and the sunflower liver protection tablets sprinted to 1 billion gold items
In the first half of 2023, China's top 10 retail pharmacy terminal liver disease Chinese patent medicine brands (unit: 100 million yuan)
Source: Minenet Grid Bureau Database
Note: Sales of less than 100 million yuan are indicated by *, and the growth rate of the red is more than 20%
Among the top 10 brands, only Pien Tze Huang of Zhangzhou Pien Tze Huang Pharmaceutical and Heilongjiang Sunflower Pharmaceutical have sales of more than 100 million yuan, and Guizhou Yibai Pharmaceutical's Shugan Yiyang Capsule is a new brand on the list.
Sales of Liver Protection Tablets in China's Retail Pharmacies in Recent Years (Unit: 100 million yuan)
Source: Minenet Grid Bureau Database
Liver protection tablets have the functions of soothing the liver and regulating qi, strengthening the spleen and eliminating appetite, and are used for the treatment of chronic hepatitis, early liver cirrhosis, fatty liver, etc. According to data from Minenet, the product has expanded rapidly in the terminal market of China's retail pharmacies in recent years, with a year-on-year increase of more than 20% in the first half of 2023, while Heilongjiang Sunflower Pharmaceutical has the largest market share, accounting for more than 90%, and has maintained a double-digit growth rate from 2021 to the first half of 2023.
Sunflower Pharmaceutical pointed out in the 2023 semi-annual report that the company has precipitated and solidified the operation mode of brand drugs, and the small sunflower children's drugs and sunflower adult high-quality drugs are operated independently and operated separately. The company unswervingly implements children's drugs as the first core strategy, and unswervingly cultivates the field of "one small, one old, and one woman" characteristic drugs, among which, while the strong growth of Sunflower Adult Adult Boutique Medicine Gold Single Product Liver Protection Tablets has completed the registration and declaration in Hong Kong, and is expected to exceed 1 billion yuan in 2023. In the future, the company will continue to strengthen the long board, take multiple measures at the same time, strengthen competitive barriers, and maintain and consolidate the company's leading edge in the OTC side.
Source: Minenet database, company announcements
Note: "China's Urban Physical Pharmacy Drug Terminal Competition Pattern", the statistical scope is: the national prefecture-level and above urban physical pharmacies, excluding county and rural pharmacies, the statistical scope is: China's online pharmacy drug terminal competition pattern, the statistical scope is: all drug data of online pharmacies nationwide, including Tmall, Jingdong and other third-party platforms and private domain platform all online pharmacy drug data, the above sales are calculated based on the average retail price of the product in the terminal. If there is any omission, please correct it!